CY1121981T1 - Μεθοδος για τον προσδιορισμο κινδυνου pml - Google Patents

Μεθοδος για τον προσδιορισμο κινδυνου pml

Info

Publication number
CY1121981T1
CY1121981T1 CY20191100584T CY191100584T CY1121981T1 CY 1121981 T1 CY1121981 T1 CY 1121981T1 CY 20191100584 T CY20191100584 T CY 20191100584T CY 191100584 T CY191100584 T CY 191100584T CY 1121981 T1 CY1121981 T1 CY 1121981T1
Authority
CY
Cyprus
Prior art keywords
determination
pml risk
pml
risk
patient
Prior art date
Application number
CY20191100584T
Other languages
English (en)
Inventor
Meena Subramanyam
Tatiana Plavina
Gary Lewis BLOOMGREN
Carmen Bozic
Sophia Lee
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47260338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121981(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of CY1121981T1 publication Critical patent/CY1121981T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Η εφεύρεση αφορά μεθόδους προσδιορισμού του κινδύνου για έναν ασθενή να αναπτύξει Προοδευτική πολυεστιακή λευκοεγκεφαλοπάθεια (PML).
CY20191100584T 2011-05-31 2019-06-03 Μεθοδος για τον προσδιορισμο κινδυνου pml CY1121981T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161491810P 2011-05-31 2011-05-31
US201161508584P 2011-07-15 2011-07-15
US201161550257P 2011-10-21 2011-10-21
US201261636588P 2012-04-20 2012-04-20
PCT/US2012/040283 WO2012166971A2 (en) 2011-05-31 2012-05-31 Method of assessing risk of pml

Publications (1)

Publication Number Publication Date
CY1121981T1 true CY1121981T1 (el) 2020-10-14

Family

ID=47260338

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100584T CY1121981T1 (el) 2011-05-31 2019-06-03 Μεθοδος για τον προσδιορισμο κινδυνου pml

Country Status (19)

Country Link
US (2) US20190227064A1 (el)
EP (3) EP4187248A1 (el)
JP (5) JP6243838B2 (el)
KR (3) KR102039751B1 (el)
CN (1) CN103635803A (el)
AU (1) AU2012262122B2 (el)
CA (1) CA2836490A1 (el)
CY (1) CY1121981T1 (el)
DK (2) DK2715352T3 (el)
ES (2) ES2729945T3 (el)
FI (1) FI3575792T3 (el)
HR (2) HRP20230186T1 (el)
HU (2) HUE061244T2 (el)
LT (2) LT2715352T (el)
PL (2) PL3575792T3 (el)
PT (2) PT3575792T (el)
RS (2) RS63989B1 (el)
SI (2) SI2715352T1 (el)
WO (1) WO2012166971A2 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3620469A1 (en) 2006-02-28 2020-03-11 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
MX2008011176A (es) 2006-03-03 2008-09-10 Elan Pharm Inc Metodos para tratar padecimientos inflamatorios y autoinmunes con natalizumab.
WO2011044553A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
PT2524060T (pt) 2010-01-11 2018-03-28 Biogen Ma Inc Ensaio para a deteção de anticorpos contra o vírus jc
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PT3575792T (pt) 2011-05-31 2023-02-28 Biogen Ma Inc Método de avaliação do risco de lmp
WO2014193804A1 (en) * 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
US20160223565A1 (en) * 2013-09-18 2016-08-04 The Johns Hopkins University Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk
ES2818823T3 (es) 2014-02-27 2021-04-14 Biogen Ma Inc Método de evaluación del riesgo de LMP
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
EP3700931A1 (en) 2017-10-26 2020-09-02 Biogen MA Inc. Extended interval dosing of natalizumab
EP4243932A1 (en) 2020-11-14 2023-09-20 Biogen MA Inc. Biphasic subcutaneous dosing regimens for anti-vla-4 antibodies
WO2022221458A1 (en) 2021-04-13 2022-10-20 Biogen Ma Inc Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
CA2398561A1 (en) 2000-01-27 2001-08-02 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
WO2007008690A2 (en) * 2005-07-08 2007-01-18 Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase a2
EP1863940B1 (en) * 2005-03-03 2012-06-06 Seedlings Life Science Ventures, LLC. Method of risk management for patients undergoing natalizumab treatment
EP3620469A1 (en) 2006-02-28 2020-03-11 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
EP2053961A4 (en) * 2006-08-09 2013-05-01 Biogen Idec Inc METHOD FOR DISPENSING A MEDICAMENT
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
FR2919804B1 (fr) * 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
EP4335932A2 (en) * 2008-11-07 2024-03-13 Adaptive Biotechnologies Corporation Methods of monitoring conditions by sequence analysis
PT2524060T (pt) * 2010-01-11 2018-03-28 Biogen Ma Inc Ensaio para a deteção de anticorpos contra o vírus jc
PT3575792T (pt) 2011-05-31 2023-02-28 Biogen Ma Inc Método de avaliação do risco de lmp
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml

Also Published As

Publication number Publication date
EP2715352B1 (en) 2019-04-24
DK3575792T3 (da) 2023-02-27
US20190227064A1 (en) 2019-07-25
ES2729945T3 (es) 2019-11-07
ES2939482T3 (es) 2023-04-24
AU2012262122B2 (en) 2016-12-08
WO2012166971A2 (en) 2012-12-06
KR20190122878A (ko) 2019-10-30
KR102039751B1 (ko) 2019-11-01
HRP20190860T1 (hr) 2019-06-28
EP2715352A2 (en) 2014-04-09
JP6243838B2 (ja) 2017-12-06
AU2012262122A1 (en) 2013-11-14
JP7128221B2 (ja) 2022-08-30
EP4187248A1 (en) 2023-05-31
FI3575792T3 (fi) 2023-03-17
LT2715352T (lt) 2019-06-10
CA2836490A1 (en) 2012-12-06
JP2014518377A (ja) 2014-07-28
KR20140038440A (ko) 2014-03-28
HRP20230186T1 (hr) 2023-03-31
RS58967B1 (sr) 2019-08-30
RS63989B1 (sr) 2023-03-31
PT2715352T (pt) 2019-06-12
KR102292563B1 (ko) 2021-08-24
PL3575792T3 (pl) 2023-03-27
PT3575792T (pt) 2023-02-28
EP3575792B1 (en) 2022-11-30
DK2715352T3 (da) 2019-05-20
SI3575792T1 (sl) 2023-04-28
HUE043339T2 (hu) 2019-08-28
KR20210107138A (ko) 2021-08-31
JP2023169307A (ja) 2023-11-29
PL2715352T3 (pl) 2019-09-30
EP2715352A4 (en) 2015-10-21
CN103635803A (zh) 2014-03-12
JP2020101556A (ja) 2020-07-02
JP6663396B2 (ja) 2020-03-11
JP7353338B2 (ja) 2023-09-29
EP3575792A1 (en) 2019-12-04
SI2715352T1 (sl) 2019-06-28
WO2012166971A8 (en) 2013-01-17
HUE061244T2 (hu) 2023-06-28
US20220011310A1 (en) 2022-01-13
LT3575792T (lt) 2023-03-10
WO2012166971A3 (en) 2013-03-07
KR102473834B1 (ko) 2022-12-02
JP2017191111A (ja) 2017-10-19
JP2022023126A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
CY1121981T1 (el) Μεθοδος για τον προσδιορισμο κινδυνου pml
IL265155A (en) A method for determining an increased risk of developing Alzheimer's disease
EA201590027A1 (ru) Способы детекции заболеваний или состояний
HK1212022A1 (en) Methods for predicting risk of developing hypertension
EA201201288A1 (ru) Способ применения реактивов гриньяра
EA201590172A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
EA201490533A1 (ru) Способы и композиции для определения статуса в отношении курения
UA110813C2 (uk) Лікування ліподистрофії
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
EA201490832A1 (ru) Биомаркеры, имеющие прогностическое значение в отношении ответа на лечение активатором альфа 7 никотиновых ацетилхолиновых рецепторов
UY33930A (es) Inhibidores novedosos de quinasas
MX360663B (es) Enfermedad tromboembolica.
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
EP3757224A3 (en) Method of assessing risk of pml
FR2987920B1 (fr) Procede de determination d'une caracteristique geometrico-morphologique, de posture ou comportementale d'un porteur d'une paire de lunettes
FR2956223B1 (fr) Lentille ophtalmique multifocale progressive
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
UY4153Q (es) Batería
BR112015009042A8 (pt) Método para identificar uma população de célula renal heterogênea adequada para implantação e/ou desencadeamento de uma resposta regenerativa
UY34329A (es) Compuestos de triazolopiridina
MA38171A1 (fr) Insuffisance rénale aigue
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event